Figure 4
![Figure 4. In vitro mutagenesis survey for resistance to Abl kinase inhibitors. The compiled results compare the outcomes of methodologically different screens, which probably accounts for the variation between reported resistance profiles. For an informative review and comparison of in vitro mutagenesis techniques, see von Bubnoff et al, 2005.37 †von Bubnoff et al recovered the 349S>L mutation only as a double mutant with 252Q>H. ‡Burgess et al recovered 252Q>H and 315T>1 in [10 μM imatinib + 25 nM dasatinib] and only 315T>I in [10 mM imatinib + 50 nM dasatinib].](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/110/7/10.1182_blood-2007-03-066936/2/zh80180706540004.jpeg?Expires=1735872710&Signature=WfSKY4RlGuZS5SgZrhTT2YrmZVsku~stkAyUX5pM7o1hYEkkf3CgkAV43cYAqen4WmvuUqcE4eGTcXfSS-xkjk6A3ZGdVnx-K7mKfD26abUITP65FH7xeYmHq0d~xy9A6XGTHSrpUsbbO8MfpsbYn8S721F2KTokwBxoamlYEk8MHVDoqc4qXMCkzzAsweqrK-tGQ0oy786cXhTGmU~lVyGwsWMT~ciRkclHorjg8GTLXq9YQEpRqLiXRMl88K0pJ6VbjY74H-L6EOnljxzAqPATX-y1O-81ebcXitUBeDYYlix8CbWMYy~KT3DpJPfQE1UZ9VoZsX2SaEqxobYeqQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
In vitro mutagenesis survey for resistance to Abl kinase inhibitors. The compiled results compare the outcomes of methodologically different screens, which probably accounts for the variation between reported resistance profiles. For an informative review and comparison of in vitro mutagenesis techniques, see von Bubnoff et al, 2005.37 †von Bubnoff et al recovered the 349S>L mutation only as a double mutant with 252Q>H. ‡Burgess et al recovered 252Q>H and 315T>1 in [10 μM imatinib + 25 nM dasatinib] and only 315T>I in [10 mM imatinib + 50 nM dasatinib].
